Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Thrombotic thrombocytopenic purpura

Thrombotic thrombocytopenic purpura

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Thrombotic thrombocytopenic purpura

3 trials tracked for Thrombotic thrombocytopenic purpura: 2 in phase 3 or 4 and 2 with published results. The most-cited published study has 73 citations.

3Trials tracked
2Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 2 Phase 2 1
  1. Phase 3 Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP) Completed · 73 cited
  2. Phase 3 Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura Completed · 4 cited
  3. Phase 2 Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura Completed

Showing the 3 most-cited and recently-updated of 3 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Ivonescimab-containing chemoimmunotherapy can trigger rare ADAMTS13 inhibitor-positive immune thrombotic thrombocytopenic purpura
Allergy & Immunology Sys. Review
Ivonescimab-containing chemoimmunotherapy can trigger rare ADAMTS13 inhibitor-positive immune thrombotic thrombocytopenic purpura New Case Highlights Rare Kidney Risk in Lung Cancer Treatment
This case report and literature review describes a patient with stage IVB lung adenocarcinoma who developed iTTP after receiving an ivonesci…
A single case report identifies a rare blood and kidney condition that can occur during specific lung cancer treatments involving ivonescima…
Frontiers Aug 4, 2026
Recombinant ADAMTS13 shows no significant difference in acute TTP events versus standard therapy or placebo in phase 2 and 3 trials
Hematology Meta-analysis
Recombinant ADAMTS13 shows no significant difference in acute TTP events versus standard therapy or placebo in phase 2 and 3 trials New drug raises enzyme levels but shows no clear benefit over standard care for TTP
This systematic review and meta-analysis evaluates recombinant ADAMTS13 in patients with congenital or acquired thrombotic thrombocytopenic …
A new treatment boosts enzyme activity in blood disorders but offers no clear advantage over standard therapy based on current evidence.
Jun 1, 2026
Meta-analysis links HLA alleles and ADAMTS13 variants to thrombotic thrombocytopenic purpura risk
Hematology Meta-analysis
Meta-analysis links HLA alleles and ADAMTS13 variants to thrombotic thrombocytopenic purpura risk Your Genes Could Predict Your Risk of This Rare Blood Disorder
This systematic review and meta-analysis synthesizes genetic associations in immune and congenital thrombotic thrombocytopenic purpura. HLA-…
Your DNA may hold clues to whether you will develop a rare but dangerous blood clotting condition, and new research is finally mapping those…
May 9, 2026